Insulet (NASDAQ:PODD) Posts Quarterly Earnings Results, Beats Estimates By $0.23 EPS

Key Points

• Insulet beat estimates with Q1 EPS of $1.42 (vs. $1.19 est.) and revenue of $761.7M (up ~34% YoY), and management raised full‑year revenue guidance to about 21–23%.
• International and product momentum remain key drivers — the company reported 45% constant‑currency revenue growth
• Operational/regulatory concerns weighed on the stock: a voluntary Medical Device Correction (~$12M GAAP charge) and an FDA communication on misreported MDRs introduced uncertainty, and shares fell about 9.7% amid analyst price‑target cuts.

Insulet (NASDAQ:PODD - Get Free Report) posted its quarterly earnings data on Wednesday. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23, FiscalAI reports. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. During the same quarter last year, the firm posted $1.02 EPS. The business's revenue for the quarter was up 33.9% on a year-over-year basis. Insulet updated its FY 2026 guidance to 6.210- EPS.

Here are the key takeaways from Insulet's conference call:

• Insulet delivered a strong Q1 with 30% constant-currency revenue growth ($762M, +34% reported), expanded adjusted operating margin +110bps, ~40% adjusted EPS growth, raised full‑year revenue guidance to 21–23%, and completed a $300M share repurchase while ending the quarter with $480M cash and full $500M credit availability.
• International momentum remains a key growth driver — 45% constant‑currency revenue growth, third consecutive quarter above 40%, broader reimbursement (now 85% of Canada) and planned market/ sensor launches including Spain and FreeStyle Libre 3 Plus in Germany and Canada.
• The product roadmap was emphasized as a catalyst — algorithm enhancements (new 100 mg target estimated to improve time‑in‑range ~5%), FreeStyle Libre 3 Plus integration, Omnipod 6 with a next‑gen algorithm in 2027, and an enrolled pivotal EVOLVE study toward a fully closed‑loop type‑2 system targeting FDA submission and a 2028 launch.
• Operational and regulatory risk from a voluntary Medical Device Correction (≈$12M GAAP charge; >150bps adjusted gross‑margin impact from E&O) and an FDA communication about misreported MDRs introduces reputational and regulatory uncertainty, although management says targeted fixes are implemented and no new adverse events have been reported.

Insulet Stock Down 9.7%

Shares of NASDAQ PODD traded down $16.25 during mid-day trading on Wednesday, reaching $151.28. The company had a trading volume of 4,460,444 shares, compared to its average volume of 1,123,353. The stock has a fifty day moving average of $212.92 and a two-hundred day moving average of $264.96. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The company has a market capitalization of $10.48 billion, a price-to-earnings ratio of 43.22, a PEG ratio of 0.99 and a beta of 1.20. Insulet has a 12-month low of $148.30 and a 12-month high of $354.88.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 beat and stronger-than-expected revenue: Insulet reported $1.42 EPS and $761.7M revenue (up ~34% YoY), topping estimates and exceeding the high end of its guidance range; management raised the annual revenue-growth outlook on strong Omnipod demand. Insulet Reports First Quarter 2026 Results
• Positive Sentiment: Product pipeline progress: Insulet initiated the EVOLVE pivotal study to advance a fully closed‑loop automated insulin delivery system, supporting longer‑term growth potential for higher‑value products. Insulet Initiates EVOLVE Pivotal Study
• Positive Sentiment: Analyst sentiment and technical setup: Some analysts and screens note the stock is technically oversold after recent declines, which could attract buyers if fundamentals remain strong. Insulet (PODD) Loses 17.3% in 4 Weeks
• Neutral Sentiment: Earnings call & transcripts available for detail: Management commentary and the slide deck give more color on margin cadence and the cadence of Omnipod shipments — important for assessing whether the beat is sustainable. Insulet (PODD) Q1 2026 Earnings Transcript
• Negative Sentiment: Guidance nuance: FY 2026 EPS guidance was provided slightly below some consensus figures (management set EPS guidance around 6.21 vs. some street estimates ~6.33), which tempers the upside from the quarter. Insulet Q1 Results & Guidance (MarketBeat)
• Negative Sentiment: Analyst price-target cut: BTIG lowered its price target from $320 to $260 (still a buy), which may signal more conservative near‑term expectations and contributed to selling pressure. BTIG Lowers Price Target (Benzinga)

Insider Activity

In related news, Director Michael R. Minogue purchased 2,030 shares of Insulet stock in a transaction dated Wednesday, February 25th. The stock was acquired at an average cost of $246.23 per share, with a total value of $499,846.90. Following the completion of the transaction, the director directly owned 17,483 shares of the company's stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.36% of the stock is owned by company insiders.

Institutional Trading of Insulet

Hedge funds have recently made changes to their positions in the stock. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Insulet in the fourth quarter worth approximately $26,000. DV Equities LLC purchased a new stake in shares of Insulet in the fourth quarter worth approximately $28,000. Mcguire Capital Advisors Inc. purchased a new stake in shares of Insulet in the fourth quarter worth approximately $29,000. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its position in shares of Insulet by 68.8% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 135 shares of the medical instruments supplier's stock worth $38,000 after purchasing an additional 55 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC purchased a new stake in shares of Insulet in the third quarter worth approximately $49,000.

Wall Street Analysts Forecast Growth

A number of analysts have commented on PODD shares. Leerink Partners reduced their price objective on shares of Insulet from $386.00 to $360.00 and set an "outperform" rating for the company in a research note on Thursday, February 19th. The Goldman Sachs Group reduced their price objective on shares of Insulet from $326.00 to $277.00 and set a "buy" rating for the company in a research note on Wednesday, April 8th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $325.00 price objective on shares of Insulet in a research note on Tuesday, April 14th. Oppenheimer reduced their price objective on shares of Insulet from $365.00 to $300.00 and set an "outperform" rating for the company in a research note on Thursday, February 19th. Finally, TD Cowen lowered shares of Insulet from a "buy" rating to a "hold" rating and set a $294.00 price objective for the company. in a research note on Monday, January 26th. Eighteen analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average target price of $324.38.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.